Full Press Release Details
Biotech Inc. to Present at BIO Investor Forum 2009
CALGARY, AB, October 23, 2009
--- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX:
ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the
Annual BIO Investor Forum 2009 on Wednesday, October 28, 2009 at 3:00
p.m. PT. The conference will be held at the Palace Hotel in San Francisco
on October 28 and 29, 2009.
audio link to the webcast presentation is available at:
, or on the company's website at www.oncolyticsbiotech.com. It
is recommended that listeners log on 15 minutes in advance of the presentation
to register and download any necessary software.
replay will be accessible approximately one hour following the presentation on
the Oncolytics website.
Investor Forum is a national investor forum to explore investment trends and
opportunities in life sciences, with a focus on public and venture-stage growth
companies as well as those poised to join the growth "watch list" in
Oncolytics Biotech Inc.
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III trial in head
and neck cancers using REOLYSIN , its
proprietary formulation of the human reovirus. For further information about
Oncolytics, please visit: www.oncolyticsbiotech.com.
The presentation and webcast times
are subject to change. This release and the presentation related thereto contain
forward-looking statements which involve known and unknown risks, delays,
uncertainties and other factors not under the Company's control and which may
cause actual results, performance or achievements of the Company to be
materially different from the results, performance or expectations implied by
these forward-looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN as a cancer treatment, the success and
timely completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company's quarterly and annual
filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable
FURTHER INFORMATION PLEASE CONTACT: